Martz E
Hum Immunol. 1987 Jan;18(1):3-37. doi: 10.1016/0198-8859(87)90110-8.
Adhesions of lymphocytes, among themselves or with other cell types, are necessary for most steps in immune responses including both induction and effector phases. Among adhesions of T cells involving specific immunological recognition, CTL-target adhesions have been the most studied. Although CTL-mediated killing is highly specific (specific/nonspecific lytic activity 50-fold), CTL-target adhesion (conjugation) is less so. In the mouse, specificity of conjugation has typically been four to eightfold. Two recent studies with cloned human CTL found much less specificity of conjugation, from one-fold (no specificity) to 1.5-fold. Thus, with cloned human CTL, adhesion may occur promiscuously with any potential target; recognition following adhesion is necessary for lethal hit delivery. The fact that antibodies to the antigen receptor (Ti or CD3) inhibit killing without inhibiting CTL-target conjugation supports this view. The ability of lymphocytes to form nonspecific adhesions, plus the dependence of even the specific mouse adhesions on temperature, metabolic energy, magnesium, and an intact cytoskeleton suggest that the bulk of the strength of T lymphocyte adhesions are not simply the sum of the bonds between antigen receptors (Ti) and antigen. Lymphocytes evidently possess separate "adhesion strengthening" mechanisms. The similarities in the properties of CTL-target adhesions and antigen-independent homotypic B lymphocyte adhesions (Table 2) suggest that at least some of these mechanisms are widely used among cells of hematopoietic origin. MoAbs to most lymphocyte surface molecules, when bound to the living lymphocyte membrane, have no evident functional effects on lymphocyte function. However, a minority can either activate or inhibit lymphocyte functions. Such antibodies identify "leukocyte (or lymphocyte) function-associated antigens," or LFAs (not all of which happen to have "LFA" in their names, Table 1). Most of the inhibitory antibodies inhibit lymphocyte adhesions, and this appears to account for their inhibitory effects on functions such as killing or proliferation. The fact that the binding of antibodies to a particular membrane glycoprotein inhibits adhesion does not guarantee that the glycoprotein in question is a direct participant in adhesion (one of the "glue" molecules). However, there is scanty evidence in support of indirect "negative signals" that may be induced by such antibodies, and direct participation of most LFAs in adhesion seems likely.(ABSTRACT TRUNCATED AT 400 WORDS)
淋巴细胞之间或与其他细胞类型之间的黏附,对于免疫反应的大多数步骤都是必要的,包括诱导阶段和效应阶段。在涉及特异性免疫识别的T细胞黏附中,CTL与靶细胞的黏附研究得最多。尽管CTL介导的杀伤具有高度特异性(特异性/非特异性裂解活性为50倍),但CTL与靶细胞的黏附(结合)特异性较低。在小鼠中,结合的特异性通常为4至8倍。最近两项对克隆的人CTL的研究发现结合特异性低得多,从1倍(无特异性)到1.5倍。因此,对于克隆的人CTL,其可能与任何潜在靶细胞随意发生黏附;黏附后的识别对于致命打击的传递是必要的。抗抗原受体(Ti或CD3)抗体抑制杀伤但不抑制CTL与靶细胞的结合,这一事实支持了这一观点。淋巴细胞形成非特异性黏附的能力,以及即使是特异性的小鼠黏附对温度、代谢能量、镁和完整细胞骨架的依赖性,表明T淋巴细胞黏附力的大部分并非简单地是抗原受体(Ti)与抗原之间键的总和。淋巴细胞显然具有独立的“黏附增强”机制。CTL与靶细胞黏附以及抗原非依赖性同型B淋巴细胞黏附的特性相似性(表2)表明,这些机制中至少有一些在造血起源的细胞中广泛使用。大多数针对淋巴细胞表面分子的单克隆抗体,当与活淋巴细胞膜结合时,对淋巴细胞功能没有明显的功能影响。然而,少数抗体可以激活或抑制淋巴细胞功能。这类抗体识别“白细胞(或淋巴细胞)功能相关抗原”,即LFAs(并非所有这些抗原的名称中都恰好有“LFA”,表1)。大多数抑制性抗体抑制淋巴细胞黏附,这似乎解释了它们对杀伤或增殖等功能的抑制作用。抗体与特定膜糖蛋白的结合抑制黏附这一事实,并不能保证所讨论的糖蛋白是黏附的直接参与者(“黏合剂”分子之一)。然而,几乎没有证据支持此类抗体可能诱导的间接“负信号”,并且大多数LFA似乎直接参与黏附。(摘要截断于400字)